Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus reuteri SD5865
- Development stage
- Preclinical
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral (capsule), Oral (fermented Food/dairy Product)[4][7]
01
Overview
Lactobacillus reuteri SD5865 is a specific probiotic bacterial strain of the species *Lactobacillus reuteri*. It has been studied for its effects on glucose metabolism and incretin hormone release in humans. In clinical trials, daily oral administration of L. reuteri SD5865 increased glucose-stimulated secretion of glucagon-like peptide 1 (GLP-1) and GLP-2, as well as insulin and C-peptide levels in healthy volunteers, suggesting enhanced incretin effect and improved glucose-dependent insulin secretion[3][8]. The mechanism appears to involve modulation of gut microbiota composition leading to increased incretin release rather than direct effects on peripheral or hepatic insulin sensitivity[3][8]. This strain is also used in fermented dairy products such as yogurt for its probiotic benefits, which may include supporting digestive health, immune function, intestinal barrier integrity, and potentially reducing gastrointestinal infections[4][7].
- Brand names
- LR Superfood (Cutting Edge Cultures, may contain this strain depending on batch)
- Other names
- Lactobacillus reuteri SD 5865L. reuteri SD5865
02
Targets
Beyond the preview
Go deeper on Lactobacillus reuteri SD5865.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus reuteri SD5865.